logo

For the Inventor, By the Inventor

Frankfort, IN, United States of America

Richard Craig Thompson

This inventor holds 21 USPTO granted patents, primarily in Glycopeptide Compounds. Top assignees: Eli Lilly and Company, Athena Neurosciences, Inc., Elan Pharmaceuticals, Inc.. Active years: 1998-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Craig Thompson. Retrieved from https://idiyas.com/inventor/richard-craig-thompson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21

% Patents Active = 66.7

Average Co-Inventor Count = 3.7

ph-index = 5

Forward Citations = 185(Granted Patents)


Company Filing History:

goldMedal15 out of 4,514 
 
Eli Lilly and Company
 patents
silverMedal1 out of 35 
 
Athena Neurosciences, Inc.
 patents
bronzeMedal1 out of 202 
 
Elan Pharmaceuticals, Inc.
 patents
4. 1 out of 52 
 
Intermune, Inc.
 patents
5. 5 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 1998-2009

Loading Chart...
Areas of Expertise:
Imidazopyridazine Compounds
Peroxisome Proliferator Agonists
N-acylation
Glycopeptide Antibiotic Derivatives
Deoxyamino Acid Compounds
Cycloalkyl Compounds
Pharmaceutical Compositions
Beta-Amyloid Inhibition
Biological Reagents
Glycopeptide Hexapeptides
Urea Derivatives
Alkylated Hexapeptides
21 patents (USPTO):Explore Patents
1. 7612067 - Imidazopyridazine compounds (2009-11-03),
2. 7544812 - Peroxisome proliferator activated receptor agonists (2009-06-09),
3. 7365053 - Selective N-acylation of A82846 glygopeptides analogs (2008-04-29),
4. 7304062 - Peroxisome proliferator activated receptor alpha agonists (2007-12-04),
5. 7205321 - Peroxisome proliferator activated receptor alpha agonists (2007-04-17),
6. 6939947 - N1-modified glycopeptides (2005-09-06),
7. 6906056 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds (2005-06-14),
8. 6838455 - Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds (2005-01-04),
9. 6774125 - Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2004-08-10),
10. 6670446 - N1 modified glycopeptides (2003-12-30),
11. 6569851 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-05-27),
12. 6552013 - Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-04-22),
13. 6509331 - Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-01-21),
14. 6486350 - Biological reagents and methods for determining the mechanism in the generation of &bgr;-amyloid peptide (2002-11-26),
15. 6037447 - Glycopeptide compounds (2000-03-14),

Title: The Innovative Journey of Inventor Richard Craig Thompson

Introduction:

Richard Craig Thompson, a prolific inventor based in Frankfort, IN (US), has made significant contributions to the field of pharmaceuticals with a total of 21 patents to his name. Known for his groundbreaking work in developing compounds for the treatment of psychiatric disorders and neurological diseases, Thompson continues to push the boundaries of innovation in medicine.

Latest Patents:

Thompson's latest patents include:

1. Imidazopyridazine Compounds: These novel compounds (Formula I) serve as corticotropin releasing factor 1 (CRF1) receptor antagonists, offering promising solutions for psychiatric disorders and neurological diseases.

2. Peroxisome Proliferator Activated Receptor Agonists: Represented by Formula I, these compounds show potential as agonists for peroxisome proliferator activated receptors, opening new doors for treating various medical conditions.

Career Highlights:

Thompson has solidified his reputation as an inventive mind through his work at companies like Eli Lilly and Company. His dedication to research and development has led to the successful filing and approval of multiple patents, showcasing his expertise in the pharmaceutical industry.

Collaborations:

Throughout his career, Thompson has collaborated with esteemed professionals in the field, including coworkers such as Stephen Charles Wilkie and James E Audia. These partnerships have strengthened his innovative endeavors, fostering a culture of creativity and excellence in his work.

Conclusion:

Inventor Richard Craig Thompson stands as a beacon of innovation in the pharmaceutical landscape, with a remarkable portfolio of patents that reflect his commitment to advancing medical science. His relentless pursuit of groundbreaking solutions underscores his legacy as a trailblazer in the field, inspiring future generations of inventors to push the boundaries of what is possible in healthcare innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…